Rumors emerged of a possible takeover bid from the Kalamazoo, Mich.-based company emerged on Monday in a Wall Street Journal report, after which both companies officially responded with statements of “no comment.”
Today, Stryker stated that it “is not in discussions with Boston Scientific regarding a potential acquisition,” according to an SEC filing. The company said that it normally doesn’t comment on such matters, but that it issued the statement in response to market speculation.
Shares in Stryker saw a significant drop after the announcement, having lost 9.1% since Monday, down $16.43 to $162.54. Stryker shares are now rebounding in pre-market trading today, up 7% at $174, as of 8:57 a.m. EDT.
Shares in Boston Scientific have fallen 6.6% in pre-market trading, at $31.60 as of 9:12 a.m. EDT.
Analysts, though surprised by the deal, said that a possible merger between the two companies could have formed a “higher growth Medtronic.”
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.